Tumour dormancy in inflammatory microenvironment: A promising therapeutic strategy for cancer-related bone metastasis
- 16 June 2020
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 77 (24) , 5149-5169
Abstract
Cancer metastasis is a unique feature of malignant tumours. Even bone can become a common colonization site due to the tendency of solid tumours, including breast cancer (BCa) and prostate cancer (PCa), to metastasize to bone. Currently, a previous concept in tumour metabolism called tumour dormancy may be a promising target for antitumour treatment. When disseminated tumour cells (DTCs) metastasize to the bone microenvironment, they form a flexible regulatory network called the “bone-tumour-inflammation network”. In this network, bone turnover as well as metabolism, tumour progression, angiogenesis and inflammatory responses are highly unified and coordinated, and a slight shift in this balance can result in the disruption of the microenvironment, uncontrolled inflammatory responses and excessive tumour growth. The purpose of this review is to highlight the regulatory effect of the “bone-tumour-inflammation network” in tumour dormancy. Osteoblast-secreted factors, bone turnover and macrophages are emphasized and occupy in the main part of the review. In addition, the prospective clinical application of tumour dormancy is also discussed, which shows the direction of future research.Keywords
Funding Information
- Natural Science Foundation of China (81930067)
- Project of Nature Science Foundation of China (31870962)
- Key Project of Logistics Research Plan of the PLA (AWS17J004-02-06)
- Medical Science and Technology Youth Cultivation Project of PLA (20QNPY022)
- Medical Innovation Capability Upgrading Plan of Southwest Hospital (SWH2018LJ-03)
- medical innovation of graduate students in chongqing (CYS19360)
This publication has 191 references indexed in Scilit:
- GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor FormationPLOS ONE, 2013
- Clinical opportunities and challenges in targeting tumour dormancyNature Reviews Clinical Oncology, 2012
- Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growthBone, 2012
- Osteocyte RANKL: New insights into the control of bone remodelingJournal of Bone and Mineral Research, 2012
- VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging α4β1-Positive Osteoclast ProgenitorsCancer Cell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Does tumour dormancy offer a therapeutic target?Nature Reviews Cancer, 2010
- TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formationNature Medicine, 2009
- A pilot study to evaluate the safety and efficacy of the long‐acting interleukin‐1 inhibitor rilonacept (interleukin‐1 trap) in patients with familial cold autoinflammatory syndromeArthritis & Rheumatism, 2008
- Inflammation and cancerNature, 2002